38,000 Shares in Viridian Therapeutics, Inc. $VRDN Bought by DCF Advisers LLC

DCF Advisers LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the second quarter, Holdings Channel reports. The firm bought 38,000 shares of the company’s stock, valued at approximately $698,000.

Several other institutional investors have also recently bought and sold shares of VRDN. KBC Group NV bought a new position in Viridian Therapeutics in the 1st quarter worth $34,000. ANTIPODES PARTNERS Ltd bought a new stake in Viridian Therapeutics during the fourth quarter valued at about $36,000. State of Wyoming acquired a new stake in shares of Viridian Therapeutics in the second quarter valued at about $43,000. Larson Financial Group LLC acquired a new stake in shares of Viridian Therapeutics in the third quarter valued at about $52,000. Finally, US Bancorp DE increased its stake in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after purchasing an additional 463 shares during the period.

Analyst Ratings Changes

VRDN has been the subject of several research analyst reports. The Goldman Sachs Group reissued a “buy” rating and set a $39.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Wall Street Zen lowered Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Evercore set a $26.00 price target on Viridian Therapeutics in a research report on Friday, May 15th. Weiss Ratings lowered Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Finally, Royal Bank Of Canada increased their price objective on Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Thirteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.93.

Viridian Therapeutics Stock Performance

VRDN opened at $24.80 on Thursday. The stock’s 50 day simple moving average is $19.49 and its 200-day simple moving average is $21.03. The company has a current ratio of 16.95, a quick ratio of 16.95 and a debt-to-equity ratio of 0.43. The stock has a market cap of $2.81 billion, a PE ratio of -7.36 and a beta of 0.91. Viridian Therapeutics, Inc. has a 1 year low of $13.18 and a 1 year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its earnings results on Thursday, August 6th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The firm had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.07 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.